Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy

NCT02215252 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02215252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02215252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2014
Completion date
September 28, 2015
Enrollment
141 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathy, painful